Literature DB >> 8762810

Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines.

A Raza1, S Mundle, V Shetty, S Alvi, H Chopra, L Span, A Parcharidou, S Dar, P Venugopal, R Borok, S Gezer, J Showel, J Loew, E Robin, S Rifkin, D Alston, B Hernandez, R Shah, H Kaizer, S Gregory.   

Abstract

The paradox of myelodysplastic syndromes (MDS) which present with pancytopenias despite cellular bone marrows (BM) was investigated by conducting detailed studies of proliferation and apoptosis in 89 MDS patients. Our results demonstrated a rapid rate of both proliferation as well as apoptosis. Levels of three cytokines, tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta (TGF-beta) and interleukin-1 beta (IL-1 beta) were measured in the same patients. High levels of TNF-alpha were found to correlate with high levels of apoptosis in 83 MDS patients (P = 0.0045). We propose a dual role for TNF-alpha (or other cytokines) in the pathogenesis of MDS. On the one hand, TNF-alpha induces apoptosis in the maturing cells causing pancytopenia while on the other, it stimulates the proliferation of the primitive progenitors accounting for the hypercellular BM frequently seen in MDS. A new model for MDS is presented. The initial abnormality probably affects a primitive hemopoietic progenitor which acquires a growth advantage leading to monoclonal hemopoiesis, which in turn makes these cells susceptible towards acquiring additional mutations and appearance of cytogenetically marked (or unmarked) clones. Cytokines such as TNF-alpha whose source is presently unknown, then contribute towards the clinical syndrome of pancytopenia and hypercellularity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8762810     DOI: 10.1016/0925-5710(96)00455-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  17 in total

1.  Defective ribosome biogenesis in myelodysplastic syndromes.

Authors:  Naomi Galili; Samir Ahmed Qasim; Azra Raza
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

Review 2.  The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes.

Authors:  David A Sallman; Alan List
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

Review 3.  Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes.

Authors:  R Tehranchi
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

4.  The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes.

Authors:  Xiang Li; A Mario Marcondes; Theodore A Gooley; H Joachim Deeg
Journal:  Blood       Date:  2010-06-18       Impact factor: 22.113

5.  Myeloid Malignancies and the Marrow Microenvironment: Some Recent Studies in Patients with MDS.

Authors:  A Mario Marcondes; Aravind Ramakrishnan; H Joachim Deeg
Journal:  Curr Cancer Ther Rev       Date:  2009-11-01

6.  Induction of myelodysplasia by myeloid-derived suppressor cells.

Authors:  Xianghong Chen; Erika A Eksioglu; Junmin Zhou; Ling Zhang; Julie Djeu; Nicole Fortenbery; Pearlie Epling-Burnette; Sandra Van Bijnen; Harry Dolstra; John Cannon; Je-in Youn; Sarah S Donatelli; Dahui Qin; Theo De Witte; Jianguo Tao; Huaquan Wang; Pingyan Cheng; Dmitry I Gabrilovich; Alan List; Sheng Wei
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

7.  Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function.

Authors:  A Mario Marcondes; Andrew J Mhyre; Derek L Stirewalt; Soo-Hyun Kim; Charles A Dinarello; H Joachim Deeg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

8.  Stroma-dependent apoptosis in clonal hematopoietic precursors correlates with expression of PYCARD.

Authors:  Andrew J Mhyre; A Mario Marcondes; Emily Y Spaulding; H Joachim Deeg
Journal:  Blood       Date:  2008-10-22       Impact factor: 22.113

Review 9.  The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes.

Authors:  Azra Raza; Naomi Galili
Journal:  Nat Rev Cancer       Date:  2012-12       Impact factor: 60.716

10.  Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes.

Authors:  Janice Gabrilove; Ronald Paquette; Roger M Lyons; Chaudhry Mushtaq; Mikkael A Sekeres; Dianne Tomita; Lyndah Dreiling
Journal:  Br J Haematol       Date:  2008-06-06       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.